JANUMET 50/850MG (SITAGLIPTIN PHOSPHATE/METFORMIN HCI)

Country: Malaysia

Bahasa: Inggeris

Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
19-01-2021
Ciri produk Ciri produk (SPC)
04-09-2020

Bahan aktif:

SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE

Boleh didapati daripada:

MERCK SHARP & DOHME (MALAYSIA) SDN BHD

INN (Nama Antarabangsa):

SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE

Unit dalam pakej:

28Tablet Tablets; 56Tablet Tablets

Dikeluarkan oleh:

Patheon Puerto Rico, Inc.

Risalah maklumat

                                _CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP)_
JANUMET
® TABLET
_ _
Sitagliptin phosphate/metformin hydrochloride (50 mg/500 mg, 50 mg/850
mg, 50mg/1000 mg)
1
WHAT IS IN THIS LEAFLET
1.
What JANUMET is used for
2.
How JANUMET works
3.
Before you use JANUMET
4.
How to use JANUMET
5.
While you are using
JANUMET
6.
Side effects
7.
Storage and Disposal of
JANUMET
8.
Product description
9.
Manufacturer and Product
Registration Holder
10.
Date of Revision
WHAT JANUMET
IS USED FOR
JANUMET is a tablet that contains
two prescription medicines,
sitagliptin phosphate (JANUVIA
®
)
and metformin, which lower blood
sugar.
Sitagliptin, a member of a
class of medicines called
DPP-4 inhibitors (dipeptidyl
peptidase-4 inhibitors), and
metformin, a member of the
biguanide class of medicines,
work together to control
blood sugar levels in patients
with type 2 diabetes mellitus.
Type 2 diabetes is also called
non-insulin-dependent
diabetes mellitus, or
NIDDM.
WHY HAS MY DOCTOR PRESCRIBED
JANUMET?
Your doctor has prescribed
JANUMET, along with diet and
exercise, to help lower your blood
sugar.
WHAT IS TYPE 2 DIABETES?
Type 2 diabetes is a condition in
which your body does not make
enough insulin, and the insulin that
your body produces does not work
as well as it should. Your body can
also make too much sugar. When
this happens, sugar builds up in the
blood. This can lead to serious
medical problems.
The main goal of treating diabetes
is to lower your blood sugar to a
normal level. Lowering and
controlling blood sugar may help
prevent or delay complications of
diabetes, such as heart problems,
kidney problems, blindness, and
amputation.
High blood sugar can be lowered
by diet and exercise, and by certain
medicines.
HOW CAN I LEARN MORE ABOUT
JANUMET AND DIABETES?
You may obtain further
information from your doctor or
pharmacist, who has more detailed
information.
HOW JANUMET WORKS

JANUMET lowers blood sugar
levels in patients with type 2
diabetes.

JANUMET helps to improve
the levels of insulin after a
meal.

JANUMET he
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                All rights reserved.
LOCAL PRODUCT CIRCULAR
LPC-MK0431A-T-052020
JANUMET®
(sitagliptin phosphate/metformin
HCl)
Tablets
I. THERAPEUTIC CLASS
JANUMET
JANUMET
(sitagliptin
phosphate/metformin
HCl)
combines
two
antihyperglycemic
agents with complementary mechanisms of action to improve glycemic
control in
patients with type 2 diabetes: sitagliptin phosphate, a dipeptidyl
peptidase 4 (DPP-4)
inhibitor, and metformin hydrochloride, a member of the biguanide
class.
Sitagliptin phosphate
Sitagliptin phosphate is an orally-active, potent, and highly
selective inhibitor of the
dipeptidyl peptidase 4 (DPP-4) enzyme for the treatment of type 2
diabetes. The DPP-4
inhibitors are a class of agents that act as incretin enhancers. By
inhibiting the DPP-4
enzyme,
sitagliptin
increases
the
levels
of
two
known
active
incretin
hormones,
glucagon-like
peptide-1
(GLP-1)
and
glucose-dependent
insulinotropic
polypeptide
(GIP). The incretins are part of an endogenous system involved in the
physiologic
regulation of glucose homeostasis. When blood glucose concentrations
are normal or
elevated, GLP-1 and GIP increase insulin synthesis and release from
pancreatic beta
cells. GLP-1 also lowers glucagon secretion from pancreatic alpha
cells, leading to
reduced hepatic glucose production. This mechanism is unlike the
mechanism seen
with sulfonylureas; sulfonylureas cause insulin release even when
glucose levels are
low, which can lead to sulfonylurea-induced hypoglycemia in patients
with type 2
05KL97
diabetes and in normal subjects. Sitagliptin is a potent and highly
selective inhibitor of
the enzyme DPP-4 and does not inhibit the closely-related enzymes
DPP-8 or DPP-9 at
therapeutic concentrations.
Sitagliptin differs in chemical structure and pharmacological
action
from
GLP-1
analogues,
insulin,
sulfonylureas
or
meglitinides,
biguanides,
peroxisome
proliferator-activated
receptor
gamma
(PPARγ )
agonists,
alpha-
glucosidase inhibitors, and amylin analogues.
Metformin hydrochloride
Metformin is an antihyperglycemic agent which improves glu
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bahasa Melayu 19-01-2021